Risk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer

Medical Oncology

Volumn 26, Issue 4, 2009, Pages 452-459

  Raji, Mukaila A ^a   Tamborello, Lynsey P ^a   Kuo, Yong Fang ^a   Ju, Hyunsu ^a   Freeman, Jean L ^a   Zhang, Dong D ^a   Giordano, Sharon H ^b   Goodwin, James S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Aging; Breast cancer; Chemotherapy; Dementia; Oncology

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; AGED; AGING; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DEMENTIA; FEMALE; HUMANS; RISK FACTORS; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70949103557     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9145-0     Document Type: Article

References (42)

1. Early Breast Cancer Trialists' CollaborativeGroup (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 717 10.1016/S0140-6736(05)66544-0 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
2. V Jenkins V Shilling G Deutsch, et al. 2006 A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer Br J Cancer 94 828 34 10.1038/sj.bjc.6603029 10.1038/sj.bjc. 6603029 1:CAS:528:DC%2BD28Xis1Gktbw%3D 16523200
3. A Goldhirsch C William WC Wood D Richard RD Gelber S Alan AS Coates B Beat Thurlimann H-J Senn 2003 Meeting highlights: international consensus panel on the treatment of primary breast cancer J Clin Oncol 21 17 3357 65 10.1200/JCO.2003.04.576 10.1200/JCO.2003.04.576 12847142 (Pubitemid 46606270)
4. A Scherwath A Mehnert B Schleimer, et al. 2006 Neuropsychological function in high- risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects Ann Oncol 17 415 23 10.1093/annonc/mdj108 10.1093/annonc/ mdj108 1:STN:280:DC%2BD287ht1Okuw%3D%3D 16357023 (Pubitemid 43329577)
5. RJ Ferguson TA Ahles 2003 Low neuropsychological performance among adult cancer survivors treated with chemotherapy Curr Neurol Neurosci Rep 3 3 215 22 10.1007/s11910-003-0081-2 10.1007/s11910-003-0081-2 12691626
6. MH Wieneke ER Dienst 1995 Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer Psycho-oncology 4 61 6 10.1002/pon.2960040108 10.1002/pon.2960040108 (Pubitemid 26093776)
7. D Crivellari M Bonetti M Castiglione-Gertsch 2001 Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Study Group Trial VII J Clin Oncol 18 1412 22
8. A Hurria K Brogan KS Panageas C Pearce L Norton A Jakubowski M Zauderer J Howard C Hudis 2005 Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy Breast Cancer Res Treat 92 151 6 10.1007/s10549-005-1410-8 10.1007/s10549-005-1410-8 1:CAS:528: DC%2BD2MXls1agsLs%3D 15986124 (Pubitemid 40933579)
9. JS Wefel R Lenzi RL Theriault RN Davis CA Meyers 2004 The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial Cancer 100 2292 9 10.1002/cncr.20272 10.1002/cncr.20272 1:CAS:528:DC%2BD2cXltFWqu7g%3D 15160331 (Pubitemid 38657875)
10. IF Tannock TA Ahles PA Ganz FS van Dam 2004 Cognitive impairment associated with chemotherapy for cancer: report of a workshop J Clin Oncol 22 2233 9 10.1200/JCO.2004.08.094 10.1200/JCO.2004.08.094 15169812 (Pubitemid 41095159)
11. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs M, et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat. 2006;98(3):343-8. doi: 10.1007/s10549-006-9171-6. (Pubitemid 44195605)
12. J Vardy S Rourke IF Tannock 2007 Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research J Clin Oncol 25 17 2455 63 10.1200/JCO.2006.08.1604 17485710 (Pubitemid 46999217)
13. C Anderson-Hanley ML Sherman R Riggs VB Agocha BE Compas 2003 Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature J Int Neuropsychol Soc 9 967 82 10.1017/S1355617703970019 10.1017/S1355617703970019 14738279 (Pubitemid 37428441)
14. CE Jansen C Miaskowski M Dodd G Dowling J Kramer 2005 A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function Cancer 104 2222 33 10.1002/cncr.21469 10.1002/cncr.21469 16206292 (Pubitemid 41579970)
15. MG Fallet A Sanfilippo P Maruff L Wlh KA Phillip 2005 The nature and severity of cognitive impairment associated with breast cancer: a meta-analysis of the current literature Brain Cogn 59 60 70 10.1016/j.bandc.2005.05.001 10.1016/j.bandc.2005.05.001 (Pubitemid 41405841)
16. TA Ahles AJ Saykin CT Furstenberg, et al. 2002 Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma J Clin Oncol 20 485 93 10.1200/JCO.20.2.485 10.1200/JCO.20.2.485 1:CAS:528:DC%2BD38XovVKhsA%3D%3D 11786578 (Pubitemid 34072533)
17. CM Bender SM Sereika SL Berga VG Vogel AM Brufsky KK Paraska CM Ryan 2006 Cognitive impairment associated with adjuvant therapy in breast cancer Psycho-Oncology 15 422 30 10.1002/pon.964 10.1002/pon.964 16097037 (Pubitemid 43826855)
18. FS van Dam SB Schagen MJ Muller W Boogerd E vd Wall ME Droogleever Fortuyn, et al. 1998 Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy J Natl Cancer Inst 90 210 8 10.1093/jnci/90.3.210 10.1093/jnci/90.3.210 9462678
19. SB Schagen FSAM van Dam MJ Muller W Boogerd J Lindeboom PF Bruning 1999 Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma Cancer 85 3 640 50 10.1002/(SICI)1097-0142(19990201)85:3<640::AID- CNCR14>3.0.CO;2-G 10.1002/(SICI)1097-0142(19990201)85:3<640::AID- CNCR14>3.0.CO;2-G 1:STN:280:DyaK1M7ptVWmug%3D%3D 10091737 (Pubitemid 29075285)
20. SB Schagen MJ Muller W Boogerd RM Rosenbrand S van Rhijn S Rodenhuis FS van Dam 2002 Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients Ann Oncol 13 1387 97 10.1093/annonc/mdf241 10.1093/annonc/mdf241 1:STN:280:DC%2BD38vjvVGjtQ%3D%3D 12196364
21. SB Schagen MJ Muller W Boogerd, et al. 2006 Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients J Natl Cancer Inst 98 1742 5 1:CAS:528:DC%2BD28XhtlCru7bM 17148777
22. S Vezmar A Becker U Bode U Jaehde 2003 Biochemical and clinical aspects of methotrexate neurotoxicity Chemotherapy 49 92 104 10.1159/000069773 10.1159/000069773 1:CAS:528:DC%2BD3sXks1Ggsrs%3D 12714818 (Pubitemid 36469805)
23. JS Wefel AE Kayle CA Meyers 2004 Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target Br J Cancer 90 9 1691 6 1:STN:280:DC%2BD2czgslSnsQ%3D%3D 15150608
24. F Keime-Guibert MJ-Y Napolitano J-Y Delattre 1998 Neurological complications of radiotherapy and chemotherapy J Neurol 245 11 695 708 10.1007/s004150050271 10.1007/s004150050271 1:STN:280:DyaK1M%2FitlChsQ%3D%3D 9808237 (Pubitemid 28468468)
25. JF Bishop J Dewar GC Toner J Smith MHN Tattersall IN Olver A Ackland, et al. 1999 Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer J Clin Oncol 17 8 2355 64 1:CAS:528:DyaK1MXltlylt7o%3D 10561297
26. J Vardy K Wong Q Yi A Park P Maruff L Wagner I Tannock 2006 Assessing cognitive function in cancer patients Support Care Cancer 14 11 1111 8 10.1007/s00520-006-0037-6 10.1007/s00520-006-0037-6 16538498 (Pubitemid 44898793)
27. FP Downie HG Fan N Houédé-Tchen Q Yi IF Tannock 2006 Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment Psychooncology 15 10 921 30 10.1002/pon.1035 10.1002/pon.1035 16477674 (Pubitemid 44612891)
28. D Schiff P Wen 2006 Central nervous system toxicity from cancer therapies Hematol Oncol Clin N 20 1377 99 10.1016/j.hoc.2006.09.004 10.1016/j.hoc.2006. 09.004 (Pubitemid 44768065)
29. Surveillance, Epidemiology, and End Results (SEER) Program ( www.seer.cancer.gov ) SEER*Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
30. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER cancer statistics review, 1975-2000. Bethesda, MD: USA National Cancer Institute; 2004. p. 748.
31. DH Taylor GG Fillenbaum ME Ezell 2002 The accuracy of Medicare claims data in identifying Alzheimer's disease J Clin Epidemiol 55 929 37 10.1016/S0895-4356(02)00452-3 10.1016/S0895-4356(02)00452-3 12393082 (Pubitemid 35246565)
32. Potosky AL, Warren JL, Riedel MA, Klabunde CN, Earle CC, Begg CB. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care. 2002;40 Suppl:IV-62-8.
33. AL Potosky GF Riley JD Lubitz RM Mentnech LG Kessler 1993 Potential for services research using a linked medicare-tumor registry database Med Care 31 732 48 10.1097/00005650-199308000-00006 10.1097/00005650-199308000-00006 1:STN:280:DyaK3szivF2hsA%3D%3D 8336512
34. SH Giordano Z Duan YF Kuo GN Hortobagyi JS Goodwin 2006 Use and outcomes of adjuvant chemotherapy in older women with breast cancer J Clin Oncol 24 18 2750 6 10.1200/JCO.2005.02.3028 10.1200/JCO.2005.02.3028 16782915 Jun 20 (Pubitemid 46630572)
35. CN Klabunde JL Warren JM Legler 2002 Assessing comorbidity using claims data: an overview Med Care 40 26 35 10.1097/00005650-200208001-00004 10.1097/00005650-200208001-00004
36. Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8):IV-55-61.
37. X Du JS Goodwin 2001 Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996 Cancer 92 4 730 7 10.1002/1097-0142(20010815) 92:4<730::AID-CNCR1376>3.0.CO;2-P 10.1002/1097-0142(20010815)92:4<730:: AID-CNCR1376>3.0.CO;2-P 1:STN:280:DC%2BD3MvpvFaiuw%3D%3D 11550141 (Pubitemid 32783056)
38. Y Harris PB Gorelick S Freels M Billingsley N Brown D Robinson 1995 Neuroepidemiology of vascular and Alzheimer's dementia among African-American women J Natl Med Assoc 87 10 741 5 1:STN:280:DyaK28%2FmtFymsg%3D%3D 7473847
39. MX Tang P Cross H Andrews DM Jacobs, et al. 2001 Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan Neurology 56 1 49 56 1:STN:280:DC%2BD3Mzjt1Cjug%3D%3D 11148235
40. M Kivipelto, et al. 2006 Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study Lancet Neurol 5 9 735 41 10.1016/S1474-4422(06)70537-3 10.1016/S1474-4422(06) 70537-3 16914401 (Pubitemid 44205512)
41. R Newcomer T Clay 1999 Misclassification and selection bias when identifying Alzheimer's disease solely from Medicare claims records J Am Geriatr Soc 47 215 9 1:STN:280:DyaK1M7ktVOqsA%3D%3D 9988293
42. DH Taylor Jr FA Sloan PM Doraiswamy 2004 Marked increase in Alzheimer's disease identified in Medicare claims records between 1991 and 1999 J Gerontol A Biol Sci Med Sci 59 762 6 15304542